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Supplemental Note 
 
Cohort Descriptions 
 
Cohorts contributing to the discovery phase: Whole-genome sequencing datasets 
 
The Avon Longitudinal Study of Parents and Children (ALSPAC)  
ALSPAC is a long-term health research project. More than 14,000 mothers enrolled during pregnancy in 
1991 and 1992, and the health and development of their children has been followed in great detail ever 
since1,2. The ALSPAC families have provided a large amount of genetic and environmental information 
during the course of this longitudinal study. The study website contains details of all the data that is 
available through a fully searchable data dictionary. Ethical approval for the study was obtained from the 
ALSPAC Ethics and Law Committee and the Local Research Ethics Committees. Study participants were 
selected to maximise phenotypic coverage, previous genome-wide array genotyping, coverage with other 
“-omic” datasets (transcriptomic, metabolomic) and consent to whole genome sequencing, but 
were otherwise representative of the original population samples. For ALSPAC, the sequenced and 
imputed samples were combined for phenotype preparation. 
 
The St Thomas’ Twin Registry (TwinsUK) 
The Department of Twin Research and Genetic Epidemiology (DTR) is the UK's only twin registry of 12,000 
identical and non-identical twins between the ages of 16 and 85 years3. The database is used to study the 
genetic and environmental aetiology of age-related complex traits and   diseases. Study participants were 
selected to maximise phenotypic coverage, previous genome-wide array genotyping, coverage with other 
“-omic” datasets (transcriptomic, metabolomic) and consent to whole genome sequencing, but 
were otherwise representative of the original population samples. 
ALSPAC and TwinsUK WGS data quality control: 
Of the 4,030 samples (1,990 TwinsUK and 2,040 ALSPAC) that were submitted for sequencing, 3,910 
samples (1,934 TwinsUK and 1,976 ALSPAC) were sequenced and went through the variant calling 
procedure. Low quality samples were removed for any of the following reasons: high overall discordance 
to GWAS genotype data, high heterozygosity, no GWAS genotype data available, or sample below 4x 
mean read-depth. Overall, 3,798 samples (1,870 TwinsUK and 1,928 ALSPAC) were brought forward to 
the genotype refinement step. After the genotype refinement further samples were removed for any of 
the following reasons, post-refinement non-reference discordance with GWAS data, multiple relations to 
other samples, or discordance with manifest gender. This left a final set of 3,781 samples (1,854 TwinsUK 
and 1,927 ALSPAC). Details on production and quality control of ALSPAC and TwinsUK WGS are described 
in 4. 
TwinsUK anthropometric traits: 
Total body and regional fat mass was measured using a dual-energy x-ray absorptiometry (DXA) scanner 
(Hologic Discovery X-Ray Bone Densitometer; Hologic Model QDR-4500W). Participants were placed with 
light clothes and without metal objects in a recumbent position on the DXA table. 
ALSPAC anthropometric traits: 
A Lunar prodigy narrow fan beam densitometer was used to perform a whole body DXA scan where bone 
content, lean and fat masses are measured. The procedure was clearly explained to the child and parent 
and parental consent was obtained before proceeding. The child was asked to lie on the Prodigy couch (in 
light clothing without any metal fastenings), with the parent sitting at least a metre away to comply with 
the IRMER legislation. The child’s height, weight, date of birth, gender and ethnicity (if appropriate) were 
entered into the computer and the machine was started. The arm of the machine moved over the child 
and two sources of X-ray scan the child. The child was reassured throughout the scan and encouraged to 
keep as still as possible. A daily QA was performed using the calibration block in accordance with the 
manufacturers recommendations. The radiation protection supervisor or deputy scanned a spine 
phantom weekly. 
 
FINRISK 
The FINRISK study is a series of population-based cardiovascular risk factor surveys carried out every five 
years in five (or six in 2002) geographical areas of Finland, including North Karelia, Northern Savo (former 
Kuopio), Southwestern Finland, Oulu Province, Lapland province (in 2002 only) and the region of Helsinki 
and Vantaa5. A stratified random sample was drawn for each survey from the national population 
register; the age-range was 25-74 years. All individuals enrolled in the study received a physical 
examination, a self-administered questionnaire, and a blood sample was drawn. The Coordinating Ethical 
Committee of the Helsinki and Uusimaa Hospital District has approved the FINRISK surveys, which 
followed the declaration of Helsinki.  
Anthropometric traits: 
At the study sites, specially trained nurses measured weight, height, waist circumference, and hip 
circumference using standardized international protocols.  All anthropometric measures were assessed 
with the participant in light clothing and with bare feet. The measurement of weight was rounded to the 
nearest 0.1 kg and height to the nearest 0.1 cm. BMI was calculated as the weight in kilograms divided by 
the squared height in meters (kg/m2). Waist circumference was measured midway between the lower rib 
margin and iliac crest. Hip circumference was measured at the level of the widest circumference over the 
buttocks. The measurements of waist and hip circumferences were rounded to the nearest 0.5 cm. Waist 
to hip ratio was calculated as waist circumference divided by hip circumference. 
 
Cohorts contributing to the discovery phase: GWAS imputed on the 1000 Genomes and UK10K 
haplotype panels 
 
ALSPAC and TwinsUK GWAS 
Additional GWAS data were used for each cohort. For ALSPAC, there were another 6,557 samples 
available, which were measured on Illumina HumanHap550 arrays 20. For TwinsUK, there were another 
2,575 samples that were unrelated to the sequence dataset (IBS>0.125) with genotypes on Illumina 
HumanHap300 or Illumina Human610 arrays 21.  
ALSPAC and TwinsUK GWAS data quality control: 
Both datasets passed QC criteria (gender check, heterozygosity, European ancestry, relatedness (ALSPAC) 
and zygosity (TwinsUK). Variants discovered through WGS of the TwinsUK and ALSPAC cohorts were 
imputed into the full GWAS genotyped cohorts increasing the sample size for single point association 
analysis up to 9,132 subjects. The combined UK10K and 1000 Genomes Project reference panel and 
imputation of it into ALSPAC and TwinsUK GWAS arrays are discussed in 4,6. 
TwinsUK anthropometric traits: 
Total body and regional fat mass was measured using a dual-energy x-ray absorptiometry (DXA) scanner 
(Hologic Discovery X-Ray Bone Densitometer; Hologic Model QDR-4500W). Participants were placed with 
light clothes and without metal objects in a recumbent position on the DXA table. 
ALSPAC anthropometric traits: 
A Lunar prodigy narrow fan beam densitometer was used to perform a whole body DXA scan where bone 
content, lean and fat masses are measured. The procedure was clearly explained to the child and parent 
and parental consent was obtained before proceeding. The child was asked to lie on the Prodigy couch (in 
light clothing without any metal fastenings), with the parent sitting at least a metre away to comply with 
the IRMER legislation. The child’s height, weight, date of birth, gender and ethnicity (if appropriate) were 
entered into the computer and the machine was started. The arm of the machine moved over the child 
and two sources of X-ray scan the child. The child was reassured throughout the scan and encouraged to 
keep as still as possible. A daily QA was performed using the calibration block in accordance with the 
manufacturers recommendations. The radiation protection supervisor or deputy scanned a spine 
phantom weekly. 
 
United Kingdom Household Longitudinal Study (UKHLS) 
The UKHLS, also known as Understanding Society is a longitudinal panel survey of 40,000 UK households 
(England, Scotland, Wales and Northern Ireland) representative of the UK population7. Participants are 
surveyed annually since 2009 and contribute information relating to their socioeconomic circumstances, 
attitudes, and behaviours via a computer assisted interview. The study includes phenotypical data for a 
representative sample of participants for a wide range of social and economic indicators as well as a 
biological sample collection encompassing biometric, physiological, biochemical, and haematological 
measurements and self-reported medical history and medication use. The UKHLS has been approved by 
the University of Essex Ethics Committee and informed consent was obtained from every participant. 
UKHLS data quality control: 
In total, 10,484 samples were genotyped on the Illumina HumanCoreExome chip (v1.0) at the Wellcome 
Trust Sanger Institute. Genotype calling was performed using GenCall and zCall. We excluded samples 
with a call rate <98% and <99% for Gencall and zCall respectively, or that were heterozygosity outliers, 
had sex discrepancies, were duplicates or that were ethnic outliers. Variants were excluded with a call 
rate below 95% and 99% for GenCall and zCall respectively, with a Hardy-Weinberg equilibrium P-value < 
10-4 or with a cluster separation score < 0.4. Prior to phasing we compared the variants to the 1000 
Genomes Project and the UK10K haplotypes and we excluded any variant for which the alleles differed 
for the same variant at the same position. In addition variants were excluded if they were a duplicate, 
monomorphic, a singleton or known to have poor clustering after inspecting the intensity data.  Samples 
were phased using SHAPEITv2 and imputed using IMPUTE v2. Unrelated samples were determined by 
performing identity by descent using the autosomal directly genotyped variants with MAF≥1% and 
filtered so that variants with a linkage-disequilibrium r2 <0.2 remained, in total 9175 unrelated samples 
were included in the analysis. 
 
Rotterdam Study cohort I (RS-I) 
The Rotterdam Study is an ongoing prospective population-based cohort study, focused on chronic 
disabling conditions of the elderly. The study comprises an outbred ethnically homogenous population of 
Dutch Caucasian origin. The rationale of the study has been described in detail elsewhere8. In summary, 
7,983 men and women aged 55 years or older, living in Ommoord, a suburb of Rotterdam, the 
Netherlands, were invited to participate in the first phase. Fasting blood samples were taken during the 
participant's third visit to the research center.  
 
Rotterdam Study cohort II (RS-II) 
The Rotterdam Study cohort II prospective population-based cohort study comprises 3,011 residents aged 
55 years and older from the same district of Rotterdam. The rationale and study design of this cohort is 
similar to that of the RS-I8. The baseline measurements took place during the first visit. The Rotterdam 
Study has been approved by the Medical Ethics Committee of the Erasmus MC and by the Ministry of 
Health Welfare and Sport of the Netherlands, implementing the “Wet Bevolkingsonderzoek: ERGO 
(Population Studies Act: Rotterdam Study)”. All participants provided written informed consent to 
participate in the study and to obtain information from their treating physicians. 
 
Rotterdam Study cohort III (RS-III) 
The Rotterdam Study is an ongoing prospective population-based cohort study, focused on chronic 
disabling conditions of the elderly. The study comprises an outbred ethnically homogenous population of 
Dutch Caucasian origin. In 2006 all residents of Ommoord aged 45 years and over and who had not been 
invited before to RSI or RSII, were asked to participate following the same rationale that in these studies. 
A total of 3,932 out 6,057 of men and women entered the study. All participants provided written 
informed consent to participate in the study and to obtain information from their treating physicians.  
Anthropometric traits for Rotterdam Study cohorts I-III: 
For all participants dual-energy x-ray absorptiometry (DXA) based bone mineral density (BMD) 
measurements of the lumbar spine, dual hip and total body BMD, as well as determination of body 
composition parameters are assessed with a ProdigyTM total body fan-beam densitometer (GE Lunar 
Corp, Madison, WI, USA). From the total body scan, we measure lean mass and fat mass body 
composition, including total body, trunk, arm, legs, and android and gynoid regions of interest9. 
 
The Ludwigshafen Risk and Cardiovascular Health (LURIC) study - controls 
The LURIC study is a prospective study of more than 3,300 individuals of German ancestry in whom 
cardiovascular and metabolic phenotypes (CAD, MI, dyslipidaemia, hypertension, metabolic syndrome 
and diabetes mellitus) have been defined or ruled out using standardised methodologies in all study 
participants. A 10-year clinical follow-up for total and cause specific mortality has been completed10. 
From 1997 to 2002 about 3,800 patients were recruited at the Heart Center of Ludwigshafen (Rhein). 
Inclusion criteria were: German ancestry, clinical stability (except for acute coronary syndromes) and 
existence of a coronary angiogram. Exclusion criteria were: any acute illness other than acute coronary 
syndromes, any chronic disease where non-cardiac disease predominated and a history of malignancy 
within the last five years. The study was approved by the ethics review committee at the 
Landesarztekammer Rheinland-Pfalz in Mainz, Germany, and written informed consent was obtained 
from the participants. 
 
1958 Birth Cohort 
Participants to the cohort have been followed-up regularly since birth with prospective information 
collected on a wide range of indicators related to health, health behaviour, lifestyle, growth and 
development. There have been 9 contacts with the participants since their birth (ages 7, 11, 16, 23, 33, 
41, 45, 47, and 50 years). The biomedical survey at age 45 years included collection of blood samples and 
DNA from about 8000 participants. The survey was approved by the South East multicentre research 
ethics committee (MREC). There was an informed consent process conducted by the National Centre for 
Social Research11. 
 
TEENs of Attica: Genes and Environment (TEENAGE) 
Participants were drawn from the TEENAGE study. A random sample of 857 adolescent students 
attending public secondary schools located in the wider Athens area of Attica in Greece were recruited in 
the study from 2008 to 2010. Our sample comprised 707 (55.9% females) adolescents of Greek origin 
aged 13.42 ± 0.88 years. Details of recruitment and data collection have been described elsewhere12. 
Prior to recruitment all study participants gave their verbal assent along with their parents’/guardians’ 
written consent forms. The study was approved by Harokopio University Bioethics Committee and the 
Greek Ministry of Education, Lifelong Learning and Religious Affairs. DNA samples were genotyped using 
Illumina HumanOmniExpress BeadChips (Illumina, San Diego, CA, USA) at the Wellcome Trust Sanger 
Institute, Hinxton, UK. Genotyping and data quality control have been described previously12. 
  
HELIC MANOLIS 
The HELIC (Hellenic Isolated Cohorts) MANOLIS (Minoan Isolates) collection focuses on Anogia and 
surrounding Mylopotamos villages. Recruitment of this population-based sample was primarily carried 
out at the village medical centres. All individuals were older than 17 years and had to have at least one 
parent from the Mylopotamos area. The study includes biological sample collection for DNA extraction 
and lab-based blood measurements, and interview-based questionnaire filling. The phenotypes collected 
include anthropometric and biometric measurements, clinical evaluation data, biochemical and 
haematological profiles, self-reported medical history, demographic, socioeconomic and lifestyle 
information. The study was approved by the Harokopio University Bioethics Committee and informed 
consent was obtained from every participant. 
 
HELIC Pomak 
The HELIC (Hellenic Isolated Cohorts) Pomak collection focuses on the Pomak villages, a set of isolated 
mountainous villages in the North of Greece. Recruitment of this population-based sample was primarily 
carried out at the village medical centres. The study includes biological sample collection for DNA 
extraction and lab-based blood measurements, and interview-based questionnaire filling. The phenotypes 
collected include anthropometric and biometric measurements, clinical evaluation data, biochemical and 
haematological profiles, self-reported medical history, demographic, socioeconomic and lifestyle 
information. The study was approved by the Harokopio University Bioethics Committee and informed 
consent was obtained from every participant. 
HELIC MANOLIS and HELIC Pomak data quality control: 
The HELIC samples were genotyped on both the Illumina HumanOmniExpress and Illumina HumanExome 
chip at the Wellcome Trust Sanger Institute. For the genotype calling we used Illuminus for OmniExpress 
and GenCall followed by zCall for the exome chip. We excluded samples with sex discrepancies, that were 
duplicates or ethnic outliers, that were heterozygosity outliers or that had a call rate <98% for 
OmniExpress and call rate <98% and <99% for Exome chip for GenCall and zCall respectively. We excluded 
variants with call rate <95%, if they had a MAF≥5%, and <99%, if they had a MAF<5% for OmniExpress and 
call rate <95% and <99% for Exome chip for GenCall and zCall respectively or that had a Hardy-Weinberg 
equilibrium P-value <10-4. We also excluded variants with a cluster separation score <0.4 for the Exome 
chip. We combined the genotypes for the OmniExpress and Exome chip into a single dataset. If a variant 
was present in both the OmniExpress and Exome array then the genotypes for those variants with 
MAF≥5% were taken from the OmniExpress whilst those with MAF <5% were taken from the Exome chip. 
Prior to phasing we compared the variants to the 1000 Genomes Project data and the UK10K haplotypes 
and we excluded any variant for which the alleles differed for the same variant at the same position. 
Variants were also excluded if they had MAF <5% and were genotyped on the OmniExpress, were 
monomorphic, a duplicate, a singleton or that were known to have poor clustering after inspecting the 
intensity data. We phased using SHAPEITv2 and imputed using IMPUTE v2. 
 
INGI-Val Borbera (INGI-VB) 
The INGI‐Val Borbera population is a collection of 1,785 genotyped samples collected in the Val Borbera 
Valley, a geographically isolated valley located within the Appennine Mountains in Northwest Italy13. The 
valley is inhabited by about 3,000 descendants from the original population, living in 7 villages along the 
valley and in the mountains. Participants were healthy people 18-102 years of age that had at least one 
grandfather living in the valley. A standard battery of tests was performed  by the laboratory of ASL 22 - 
Novi Ligure (AL), on sera from fasting blood collected in the morning. The project was approved by the 
Ethical committee of the San Raffaele Hospital and of the Piemonte Region.  All participants signed an 
informed consent. 
 
INGI-Friuli Venezia Giulia (INGI-FVG) 
The Friuli Venezia Giulia population represents a collection of six villages covering a total area of 7858 
km2 in a hilly part of Friuli-Venezia Giulia (FVG) county located in north-eastern Italy. A recent study14 
characterized this population as a genetic isolate with high level of genomic homozygosity and elevated 
linkage disequilibrium. The cohort accounts for 1,590 genotyped samples. Participants were randomly 
selected people 3-92 years of age. Genotyping and phenotyipic data for 1,590 samples are available. 
People with age <18 were excluded from analyses. A written informed consent for participation was 
obtained from all subjects. The project was approved by the Ethical committee of the IRCCS Burlo-
Garofolo. 
 
INGI-Carlantino (INGI-Carl) 
Carlantino is a small village in the Province of Foggia in southern Italy. Genetic analyses of chromosome Y 
haplotypes as well as mitochondrial DNA show that Carlantino is a genetically homogeneous population 
and not only a geographically isolated village14. Participant were randomly selected in a range of 15 – 90 
years of age. Genotyping and phenotypic data are available for 630 individuals. People with age <18 were 
excluded from analyses. Subjects gave their written informed consent for participating in these studies. 
The project was approved by the local administration of Carlantino, the Health Service of Foggia Province, 
Italy, and ethical committee of the IRCCS Burlo-Garofolo of Trieste. 
 
Arthritis Research UK Osteoarthritis Genetics (arcOGEN) 
arcOGEN is a collection of unrelated, UK-based individuals of European ancestry with knee and/or hip 
osteoarthritis (OA) from the arcOGEN Consortium15,16. Cases were ascertained based on clinical evidence 
of disease to a level requiring joint replacement or radiographic evidence of disease (Kellgren–Lawrence 
grade ≥2). The arcOGEN study was ethically approved, and all subjects used in this study provided 
written, informed consent.  
 
INCIPE 
For the INCIPE study, 6200 randomly chosen individuals, all of European descent and at least 40 years of 
age as of 1 January 2006, received a letter inviting them to participate in the study. A total of 3870 
subjects (62%) accepted and were enrolled. The ethics committees of the involved institutions approved 
the study protocol. Two studies were included in the analysis: 
1.     INCIPE1: Individuals genotyped on HumanOmniExpress-12v1-Multi_B 
2.     INCIPE2: Individuals genotyped on HumanCoreExome-12v1 
 
London Life Sciences Prospective Population Study (LOLIPOP) 
LOLIPOP is an ongoing community prospective cohort of 17,606 Indian Asian and 7,766 European men 
and women aged 35-75 years, recruited in West London, UK, to study the environmental and genetic 
factors that contribute to cardiovascular disease among UK Indian Asians17,18. Indian Asian participants 
reported having all four grandparents born on the Indian subcontinent, while European participants are 
self-classified whites born in Europe. For the current study, only white individuals were included in the 
primary meta-analysis. All participants provided written consent including for genetic studies. The 
LOLIPOP study is approved by the local Research Ethics Committees. 
Three studies were included in the analysis: 
1. LOLIPOP_EW_A: European whites from the general population, genotyped on Affymetrix 500K arrays. 
2. LOLIPOP_EW_P: European whites from the general population, enriched by subjects with metabolic 
syndrome, genotyped on Perlegen custom array. 
3. LOLIPOP_EW610: European whites from the general population, genotyped on Illumnia Human610 
array. 
 
Cohorts contributing to the follow-up effort: In silico follow-up  
 
SardiNIA 
The SardiNIA study is a longitudinal population-based cohort study started in 2001 to study quantitative 
traits of biomedical relevance with a special emphasis on those influencing aging. In a first survey, the 
project recruited individuals from four towns in the Lanusei Valley (east-central Sardinia) and assessed 98 
quantitative traits including over 62% of the eligible population living in the region (age 14-102 years), 
and at least 96% of the initial cohort have all grandparents born in the same province. The initial group of 
6,148  individuals included 4,933 phenotyped sib pairs, 4,266 phenotyped parent-child pairs, >4,069 
phenotyped cousin pairs, and >6,459 phenotyped avuncular pairs. Recently, the study recruited 773 
additional individuals, involving a total of 6,921 subjects. The longitudinal study, now in its 14th year and 
in its fourth phase, collected the longitudinal information on more than 1000 quantitative traits, including 
inflammatory markers and  immuno-related traits, that can be scored on a continuous scale19,20. A written 
informed consent was obtained from all participants. 
Quality control: 
Samples having sex discordance or with call rate lower than 98% were removed from the analyses. 
SNPs with call rate lower than 98%, HWE P-value <10-6, at least 1 mendelian errors in more than 1% of the 
available families, monomorphic and with more than 1 discordance in 13 twin pairs were removed from 
the analyses. 
 
GenerationR (GenR) 
This study was embedded in the Generation R Study, a population-based prospective cohort study from 
fetal life onwards in Rotterdam, the Netherlands. The Medical Ethics Committee of the Erasmus MC, 
University Medical Center, Rotterdam, has approved the study and written informed consent was 
obtained for all participants. All children were born between April 2002 and January 2006. Enrollment 
was aimed at early pregnancy, but was allowed until birth of the child. In total, 9,778 mothers and their 
children were included in the study.  Details of recruitment and data collection have been described in 
detail elsewhere21,22. The current analysis includes those children with genome-wide scan data that had a 
DXA scan around the age of six years. 
Anthropometric traits: 
Total body and regional fat mass was measured using a dual-energy x-ray absorptiometry (DXA) scanner 
(iDXA, 2008; GE-Lunar) and analyzed with the enCORE software, version 12.6 (GE-Healthcare). DXA can 
accurately detect whole-body fat mass within less than 0.25% coefficient of variation. Children were 
placed without shoes, heavy clothing, and metal objects in supine position on the DXA table. Total fat 
mass (kilograms) was calculated as a percentage of total body weight (kilograms) measured by DXA. The 
fat mass index (body fat mass/height2), and lean mass index (body lean mass/height2) calculated23. 
Quality Control: 
Cord blood for DNA isolation was available in 58% of all live-born participating children. Sex-mismatch 
rate between genome based sex and midwife-record based sex was low (<0.5%), indicating that possible 
contamination of maternal DNA was extremely low. Missing cord blood samples were mainly due to 
logistical constraints at the delivery. GWAS scans were run using the Illumina 610 Quad and 660 
platforms. IMPUTE2 software was used to impute genotypes to the combined UK10K-1000 genomes 
panel. Before imputation, SNPs were excluded if they had high levels of missing data (SNP call rate <98%), 
strong departures from Hardy-Weinberg equilibrium (P-value <1x10-6), or low MAF (<0.1%). 
 
UK Biobank  
500,000 participants aged 40-69 years were recruited between 2006 and 2010 in 22 assessment centres 
throughout the UK24. The assessment visit included electronic signed consent; a self-completed touch-
screen questionnaire; brief computer-assisted interview; physical and functional measures; and collection 
of biological samples and genetic data.  
Anthropometric traits: 
BMI was calculated (kg/m2) using measured height and weight. Weight (kg) was measured using the 
Tanita BC-418 MA body composition analyser (accurate to within 0.1kg) after removal of heavy clothing 
and shoes. Standing height (cm) was measured without shoes using a Seca 202 height measure. Waist 
circumference (cm) at the level of the umbilicus and hip circumference was measured using a Wessex 
non-stretchable sprung tape measure.  
Data Quality Control: 
All the analyses were carried out in Europeans. Subjects with high heterozygosity, low call rate, related 
participants, and pregnant women were further excluded from analyses. SNP genotypes were called by 
Affymetrix, and any SNPs failed by Affymetrix batch-specific QC thresholds were set to missing in all 
subjects from that batch. Additional SNP QC steps were carried out by the UK Biobank team, in which 
SNPs at certain batch/plates were set to missing if their genotype distributions were significantly different 
from other batches/plates (P-value <10-12), or there were significant deviations of genotype frequencies 
from those expected under Hardy-Weinberg equilibrium (P-value <10-12). Imputation was carried out, 
with the combined reference panel of 1000 Genomes phase 3 and UK10K data. Any variants imputed, 
with minor allele frequency of <0.001% were filtered. Association results from SNPs with imputation 
quality score <0.3 were discarded. 
 
Cohorts contributing to GoT2D: 
 
WGS 
 
Diabetes Genetics Initiative (DGI) 
Details of the samples have been described elsewhere25. For sequencing, we selected individuals from the 
phenotypic extremes using T2D liability scores calculated based on disease status, age, BMI, and sex26. 
We chose individuals from the studies used for the DGI GWAS, the Scania Diabetes Registry27, and the 
Malmö Preventive Project28. We prioritized early-onset cases with low BMI and older controls with high 
BMI; we excluded cases with age of diagnosis<35 years to minimize inclusion of individuals with type 1 
diabetes (T1D).        
 
Finland-United States Investigation of NIDDM Genetics (FUSION) 
Details of the samples have been described elsewhere29. For sequencing, we chose T2D cases from 
FUSION families with ≥2 first-degree relatives with T2D and selected one individual per family with either 
available GWAS data or earliest age at diagnosis. Remaining cases were chosen from the FUSION 
replication set, selecting those with earlier age at diagnosis from among those with Metabochip data and 
age at diagnosis≥35 years. Unrelated normal glucose tolerant (NGT) controls with age≤80 years were 
frequency matched to the cases by birth province and, within each birth province, controls with the 
highest age (in years) + 2×BMI (in kg/m2) were prioritized. All selected individuals had BMI≥18.5 kg/m2.   
 
Cooperative Health Research in the Region of Augsburg (KORA) 
Details of the samples have been described elsewhere30-32. For sequencing, we prioritized cases with ≥1 
first-degree relative with T2D (self-reported). We then chose individuals with BMI≤30 kg/m2 and age of 
diagnosis<65 years, or BMI≤33 kg/m2 and age of diagnosis≤60 years. We selected controls from KORA F4 
who were either >60 years of age with BMI>32 kg/m2, or >65 years of age with BMI>31 kg/m2. 
 
United Kingdom T2D Genetics consortium (UKT2D) 
Details of the samples have been described elsewhere33-35. For sequencing, we chose cases from the 
Wellcome Trust Case Control Consortium (WTCCC) and controls from the TwinsUK study. For cases, we 
excluded females with age of diagnosis≥66 years or BMI≥32 kg/m2, and males with age of diagnosis≥62 
years or BMI≥31 kg/m2. We ranked the remaining samples by age and BMI; we multiplied the two ranks 
and selected individuals with the lowest product of ranks. For controls, we considered twin pairs (a) with 
no recorded family history of diabetes; (b) with neither twin ever recorded as impaired glucose tolerant 
(fasting glucose [FG]>6.1mmol/l); and (c) who had available quantitative trait and GWAS data and no 
evidence of admixture in analysis of the GWAS data. From qualifying twin pairs, we chose the twin with 
the lowest ratio of FG level to BMI across all readings, giving priority to unrelated individuals with the 
lowest FG/[BMI×age] ratio. We performed pairwise sample matching between cases and possible 
controls using the first two principal components from an analysis of previously available genome-wide 
genotyping data, with the best control for each case selected.   
 
Imputed GWAS 
 
Diabetes Genetics Initiative (DGI) 
Details of the samples and GWAS have been described elsewhere25. The current analysis included 899 
T2D cases and 1,057 NGT controls from Sweden or Finland. The Finnish samples were predominantly 
from the Botnia region of Finland and the Swedish samples from Southern Sweden and Skara. T2D cases 
from both countries met WHO 1999 criteria with FG≥7.0 mmol/l or 2-hour glucose≥11.1 mmol/l during an 
oral glucose tolerance test. Cases had age of diagnosis >35 years and no detectable anti-GAD antibodies 
(defined as anti-GAD antibody levels <32 IU/ml in the Finnish samples and <1.3 anti-GAD relative units in 
the Swedish). Controls had no first-degree relatives with T2D. Cases and controls were matched on age 
(within 5 years), sex, BMI, and geographic region. Samples were genotyped using the Affymetrix Human 
Mapping 500K array. 
 
Estonian Genome Center of the University of Tartu (EGCUT) 
Details of the samples have been described elsewhere36. The current analysis included 469 T2D cases and 
7,781 population-based controls from the Estonian Biobank cohort, a volunteer-based sample of the 
Estonian resident adult population aged ≥18 years. T2D diagnosis was based on standardized health 
examination together with questionnaires on health-related topics as described in WHO ICD-10. Data are 
regularly updated through linkage to national databases and registries. Controls represent a random 
subset of the Estonian population. Participants were genotyped with either the Illumina HumanHap 370K 
array (EGCUT-370K, 80 cases and 1,768 controls) or the Illumina OmniExpress array (EGCUT‐OMNI, 389 
cases and 6,013 controls). GWAS analysis was performed separately in the two subsets. 
 
Finland-United States Investigation of NIDDM Genetics (FUSION) 
Details of the samples and GWAS have been described elsewhere29. The GWAS sample for imputation 
included 1,060 T2D cases and 1,090 NGT controls of Finnish origin. 688 T2D cases were selected one per 
family from T2D affected sibling pairs; 372 were from the population-based Finrisk 2002 study. NGT 
controls included 272 spouses of FUSION study subjects, 188 individuals who were NGT at ages 65 and 
70, and individuals from Finrisk 2002. Cases were defined by WHO 1999 criteria of FG≥7.0 mmol/l or 2-
hour plasma glucose≥11.1 mmol/l, by reported diabetes medication use, or based on medical record 
review. FUSION cases were excluded if they had known or probable T1D among first-degree relatives. 
Controls were NGT as defined by WHO 1999 criteria. Cases and controls were approximately frequency 
matched by 5-year age category, sex, and birth province. Samples were genotyped using the Illumina 
HumanHap300 array. 
 
METabolic Syndrome In Men (METSIM) 
The cross-sectional METSIM Study includes 10,197 men, aged from 45 to 73 years, randomly selected 
from the population register of the Kuopio town, Eastern Finland, and examined in 2005-2010. The aim of 
the study is to investigate genetic and non-genetic factors associated with the risk of type 2 diabetes 
(T2D), cardiovascular disease (CVD), and insulin resistance –related traits in a cross-sectional and 
longitudinal setting37,38. Study protocol includes e.g. collection of data on CVD risk factors (smoking, 
exercise, diet, history of chronic diseases including coronary heart disease, stroke, cardiac failure, 
medication, history of diabetes or early onset coronary heart disease in the family), questionnaire on the 
FINDISC Score, measurement of height, weight, waist circumference, hip circumference, blood pressure 
(3 times), and bioimpedance for the evaluation of fat percentage. 
 
Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) 
Details of the samples and GWAS have been described elsewhere39,40. Participants were randomly 
sampled from all men and women aged 70 years living in Uppsala County in 2001. This analysis included 
111 T2D cases and 838 non-T2D controls of Swedish descent. T2D status was defined by fasting blood 
glucose>6.1 mmol/l or known diabetes. Controls were non-T2D individuals. All samples were genotyped 
with the Illumina Metabochip and Illumina OmniExpress array. 
 
Uppsala Longitudinal Study of Adult Men (ULSAM) 
All men born between 1920 and 1924 in Uppsala, Sweden were invited to participate at age 50 years in 
this longitudinal cohort study that was started in 1970. Participants were reinvestigated at ages 60, 70, 
77, 82, and 88 years41. Our analysis included 166 T2D cases and 953 non-T2D controls of Swedish descent. 
T2D status was defined as hospital discharge register-defined diabetes before 2002. Controls were non-
T2D individuals. All samples were genotyped with the Illumina Metabochip and Illumina HumanOmni2.5 
array.    
 
Cohorts contributing to the follow-up effort: De novo follow-up  
 
Fenland 
The Fenland Study is an ongoing, population-based cohort study (started in 2005) designed to investigate 
the association between genetic and lifestyle environmental factors and the risk of obesity, insulin 
sensitivity, hyperglycemia and related metabolic traits in men and women aged 30 to 55 years42. Potential 
volunteers were recruited from General Practice sampling frames in the Fenland, Ely and Cambridge 
areas of the Cambridgeshire Primary Care Trust in the UK. Exclusion criteria for the study were: prevalent 
diabetes, pregnant and lactating women, inability to participate due to terminal illness, psychotic illness, 
or inability to walk unaided. All participants had measurements done at the MRC Epidemiology Unit 
Clinical Research Facilities in Ely, Wisbech and Cambridge. Participants attended after an overnight fast 
for a detailed clinical examination, and blood samples were collected. The Local Research Ethics 
Committee granted ethical approval for the study and all participants gave written informed consent. 
Sequenom genotyping: 
Genotyping was performed using the iPLEX® Assay and the MassARRAY® System (Agena Bioscience, Inc.). 
Assays for all SNPs were designed using the eXTEND suite and MassARRAY Assay Design software version 
4.0.0.2 (Agena Bioscience, Inc.). Amplification was performed in a total volume of 5µL containing ~10ng 
genomic DNA, 100nM of each PCR primer, 500µM of each dNTP, 1.25 x PCR buffer (Qiagen), 1.625mM 
MgCl₂ and 1U HotStar Taq® (Qiagen). Reactions were heated to 94 °C for 15 min followed by 45 cycles at 
94°C for 20 s, 56°C for 30 s and 72°C for 1 min, then a final extension at 72°C for 3 min. Unincorporated 
dNTPs were SAP digested prior to iPLEX™ allele specific extension with mass-modified ddNTPs using an 
iPLEX reagent kit (Agena Bioscience, Inc.). SAP digestion and extension were performed according to the 
manufacturer’s instructions with reaction extension primer concentrations adjusted to between 0.7-
1.8µM, dependent upon primer mass. Extension products were desalted and dispensed onto a 
SpectroCHIP using a MassARRAY Nanodispenser prior to MALDI-TOF analysis with a MassARRAY Analyzer 
Compact mass spectrometer. Genotypes were automatically assigned and manually confirmed using 
MassARRAY TyperAnalyzer software version 4.0 (Agena Bioscience, Inc.). 
Sequenom Data Quality Control: 
Samples were removed if their call rate was <80%. SNPs were removed if their call rate was <80%, HWE P-
value <10-4 and if the gender in the manifest was discordant with the gender in the Sequenom iPLEX 
assay. 
Anthropometric traits: 
Body composition measurements of fat mass were measured by total body DXA scans (GE Lunar Prodigy 
Advanced, GE Medical Systems, Hatfield, UK). Results were acquired and analysed within the enCORE 
software (Version 10.51.006 to 16, GE Medical Systems) under basic analysis settings. Participants were 
positioned according to the total body measurement and analysis protocol recommended by the 
manufacture.  Participants body composition results were recalculated by the symmetry and ½ body 
method when appropriate (replacing omitted left arm or body with right arm or body data). Volunteers 
were excluded if pregnancy could not be ruled out and if weight exceeded 136kg. 
 
Copenhagen General Population Study (CGPS) 
This general population study was initiated in 2003 with ongoing enrolment43,44. BMI and ischemic heart 
disease endpoints have been collected from 1976 to May 2009. Individuals were selected on the basis of 
the national Danish Civil Registration System to reflect the adult Danish population aged 20–100 y. All 
participants were white and of Danish descent; this information is available through the national Danish 
Central Person Registry. Data were obtained from a questionnaire, a physical examination, blood 
samples, and from DNA. At the time of genotyping 59,883 participants had been included; of these, 5,270 
were used as controls in the Copenhagen Ischemic Heart Disease Study, leaving 54,613 for analyses in the 
CGPS. The study was approved by Danish ethical committees and Herlev Hospital. 
 
Dataset used for mQTL analyses 
ARIES Data 
The Accessible Resource for Integrative Epigenomic Studies (ARIES) dataset represents genome-wide DNA 
methylation levels on ALSPAC samples selected from 1,018 mother-child pairs at three time points in 
children and two time points in their mothers45. A DNA sample was extracted from cord blood drawn 
from the umbilical cord upon delivery or peripheral blood according to standard procedures. Written 
informed consent has been obtained from all ALSPAC participants. Ethical approval for the study was 
obtained from the ALSPAC Ethics and Law Committee and the Local Research Ethics Committees. Samples 
were bisulfite converted using the Zymo EZ DNA MethylationTM kit and genome-wide methylation was 
measured using the Illumina HumanMethylation450 BeadChip. Methylation data were normalized in R 
with the wateRmelon package46 using the Touleimat and Tost47 algorithm to reduce the non-biological 
differences between probes. Data were then rank-normalized to remove outliers, and regressed on all 
covariates, plus bisulphite-converted DNA plate batch to remove potential batch effects (with missing 
values set to probe mean). Children were genotyped using the Illumina HumanHap550 quad genome-
wide SNP genotyping platform by the Wellcome Trust Sanger Institute and the Laboratory Corporation of 
America. Mothers were genotyped using the Illumina human660W-quad genome-wide SNP genotyping 
platform at the Centre National de Génotypage. Genotypes were phased together using SHAPEIT, and 
then imputed against the 1000 Genomes reference panel (phase 1 version 3) using Impute. The final 
imputed dataset contained 8,074,398 SNPs keeping SNPs that have Hardy-Weinberg equilibrium P-value 
>5×10-7, MAF>1% and imputation quality score >0.8. Each SNP in the imputed datasets was analysed 
against all CpG sites in the Illumina HM450 with the exception of those failing QC, and those reported to 
map to more than one location (N 19,834) or to contain a genetic variant at the CpG site (N 74,182)48. 
Association analysis of SNPs with CpG sites was performed using an additive model (rank-normalized CpG 
methylation on SNP allele count) using Matrix eQTL49. SNP effects from this analysis that were P-value 
<10-7 were then taken forward for re-analysis in PLINK to perform exact linear regression including 
covariates. Covariates included in all analyses were age (excluding birth), sex (children only), the top 10 
ancestry principal components, bisulfite conversion batch and estimated white blood cell counts (using an 
algorithm based on differential methylation between cell types50).  
 
Annotations of newly reported variants  
 
Variants associated with height: 
rs61734601 (stage 1 and 2 weighted effect allele frequency [WEAF] 8.2%, beta=-0.113, P-value=1.38x10-
101) is 359kb away from the physically closest positive control variant (Table S14). It is located in the intron 
of PPP1CA and a non-coding exon of CARNS1, but is reported as significantly associated with expression 
of RAD9A, a DNA repair gene 20kb downstream, in several different tissues in the GTEx51 portal. DNA 
repair genes have previously been linked to growth disorders52. rs61734601 is in high LD (r2=0.82) with 
rs553917782, a 6-nucleotide insertion 10bp upstream of RAD9A. The 8 following nucleotides are 
conserved (mean GERP53 score 2.2) and occur near the centre of a DNase hypersensitivity peak that 
coincides with nucleosome depletion in multiple tissues from the Roadmap Epigenomics54 project, 
indicating likely transcription factor binding (Figure S15). 
 
rs41271299 (WEAF 5.5%, beta=0.123, P-value=1.90x10-71) resides in the intron of ID4, in a highly 
conserved region (the flanking 20 bases are completely conserved in a 17-way mammalian alignment55 
and the GERP score53 at the variant site is 5.8) (Table S16). The variant resides 23bp from the final 
acceptor splice site in the gene, therefore potentially disrupting splicing, and the region is annotated as 
open chromatin in diverse tissues56 (Figure S15). 
 
rs114976626 (WEAF 2.7%, beta= -0.096, P-value=5.00x10-20) is a missense variant in SSC5D. SSC5D and its 
secreted protein product are poorly characterized. rs114976626 causes a conservative alanine to valine 
mutation in a linker sequence connecting two scavenger receptor cysteine-rich (SRCR) domains57. The 
expression of SSC5D can be detected in many tissues51, and the presence of the protein product 
throughout the entire body58. Proteins belonging to the scavenger receptor family are involved in the 
innate immune response59. 
 
rs6930571 (WEAF 17.9%, beta=0.038, P-value=6.01x10-18) is a regulatory region variant that overlaps with 
a CTCF binding site, and has been identified as eQTL for 13 genes in 26 tissues51. rs6930571 is associated 
with the expression of RNF551, a E3 ubiquitine ligase gene located 231kb downstream. Animal models 
show that the mutation of this gene causes abnormal muscle regeneration60. Aberrant expression of 
RNF5 is observed in various human myopathies60. rs6930571 is also associated with the expression of 
CYP21A251. The protein product of this gene catalyzes the 21-hydroxylation of steroids, involved in 
adrenal synthesis of mineralocorticoids and glucocorticoids61. Abnormalities of this gene cause congenital 
adrenal hyperplasia, a common recessive disease due to defective synthesis of cortisol, characterized by 
androgen excess leading to ambiguous genitalia in affected females, rapid somatic growth during 
childhood in both sexes with premature closure of the epiphyses and short adult stature. The minor allele 
of rs6930571 is associated with lower plasma cortisol in the CORNET GWAS meta-analysis62, although the 
association is not significant (EAF=18%, beta= -0.023, standard error=0.016, P-value=0.168, sample size 
12,592). 
 
rs202238847 (WEAF 2.23%, beta=0.095, height P-value=3.76x10-17) causes a single base pair deletion in 
an intron of CCDC36, which is expressed in skin/skeletal muscle and testis/ovary in the fetal and adult 
body, respectively51. LAMB2 is located 93kb upstream of rs202238847 and is involved in growth 
retardation and decreased body weight in mice63. 
 
rs4360494 (WEAF 44.7%, beta=0.024, P-value=8.98x10-13) is captured by rs4072980 (r2=0.84) in 64 with P-
value=3.1x10-6. rs4360494 has an effect on the expression on multiple genes51: FHL3, SF3A3, INPP5B, 
RP11-109P14.10, UTP11L, MTF1. The cytoskeleton associated protein product of FHL3 plays an important 
role in myogenesis through its binding partner MyoD65. Overexpression of this gene in mouse myoblast 
cells results in the retarded myotube formation and decreases the expression of muscle-specific 
regulatory genes such as myogenin65. INPP5B is a protein coding gene 43kb upstream involved in PI3K 
signaling pathway. INPP5B might play a role in Lowe’s syndrome which is characterized by short stature66. 
MTF ,located 130kb upstream from rs4360494, has been associated with hypothyroidism67, often 
characterized by slow growth rate and its protein product activates metal response genes.  
 
rs13059073 (WEAF 45.5%, beta=0.022, P-value=3.23x10-11) is captured by rs1047898 (r2=0.98) in 64 with P-
value=4.6x10-6. rs13059073 is an intergenic variant located 7kb downstream of WNT5A, whose secreted 
product (Wnt-5a) is the primary ligand in the non-canonical Wnt signalling pathway, and a regulator of 
chondrogenesis68. Mutations within this gene were shown to cause the autosomal dominant Robinow 
syndrome, which is characterized by skeletal dysplasia, limb shortening and other abnormalities69. 
Shortened body length, and various skeletal abnormalities were also described in animal models70. 
Members from the non-canonical Wnt signalling pathway have already implicated in the determination of 
height (eg. ROR2). rs17711489 is associated with the expression of WNT5A51 and is in LD with our signal 
(r2=0.25). 
 
rs4303473 (WEAF 38.0%, beta=0.022, P-value=4.08x10-11) is an intronic variant in CRISPLD2, which is 
involved in the assembly of the extracellular matrix and has been linked with  abnormal embryo size in 
mice71.  
 
rs16888802 (WEAF 17.6%, beta=0.028, P-value=5.49x10-11) is located 4kb downstream of NKX3-2, which 
encodes  a transcription factor with an important role in development and chondrocyte regulation72. Rare 
frameshift mutations of this gene are observed in spondylo-megaepiphyseal-metaphyseal dysplasia, a 
skeletal dysplasia characterized by disproportionate short stature 73. 
 
rs183677281 (WEAF 2.4%, beta= 0.071, P-value=1.24x10-10) is an intron of the principal74 transcript of 
TGFB2 and a promoter flanking region (ENSR00001598375) active in skeletal muscle myotubes, umbilical 
vein endothelial cells, astrocytes, fibroblasts75. The protein coded by TGFB2 is a transforming growth 
factor involved in various developmental processes76. Animal models of this gene show diverse 
phenotypes including defects of musculoskeletal system and morphology76. TGFB2 has already been 
linked to height by several studies64,77,78 but the reported associations are independent of our signal 
(Table S14). 
 
rs1848053 (WEAF 24.8%, beta= -0.024, P-value=2.00x10-10) is associated with the expression of FBN151, 
which is involved in a series of developmental disorders affecting the musculoskeletal system79-81.  
 
rs62038850 (WEAF 2.7%, beta= 0.071, P-value=2.45x10-10) overlaps with the 3’ untranslated region of the 
principal transcript of the ubiquitously expressed gene PGP. Phosphoglycolate phosphatase, the protein 
product of this gene, regulates the cellular levels of glycerol-3-phosphate a metabolic intermediate of 
glucose, lipid and energy metabolism57. rs62038850 is 1kb away from BRICD5, whose integral membrane 
protein product is mainly found in prostate, pancreas, salivary gland, gastric chief cells, glandular cells in 
cervix and endometrium82. rs62038850 is also 3kb away from MLST8, whose protein product is part of the 
mTOR complex, therefore involved in the regulation of cell growth and survival57. The highest levels of the 
broadly expressed protein product can be detected in skeletal muscle, heart and kidney83. Animal models 
of MLST8 show growth/body-size phenotypes including embryotic growth retardation and decreased 
embryo size84. CASKIN1 is located 16kbp away coding a scaffolding protein and is expressed mainly in 
brain58. MLST8 and CASKIN1 have already been associated with height77, but the reported signals are 
independent from rs62038850 (Table S14). E4F1 is a ubiquitously expressed protein coding gene 10kb 
away from rs62038850, the protein product of this gene is a transcriptional repressor regulating cell 
proliferation and survival57. Animal models show mutation of E4F1 can cause decreased embryo size85. 
 
rs142854193 (WEAF 2.3%, beta=0.071, P-value=1.31x10-9) is a novel height variant overlapping with the 
3’ untranslated region of the principal74 transcript of the protein coding gene FKBP9 and an intron of 
protein coding gene AVL9. AVL9 is a poorly characterized gene, its protein product is a single pass 
membrane protein potentially involved in cell migration, endosome trafficking86. Misregulation of the 
expression of this protein causes secretory defects in yeast86. FKBP9 is a chaperone: it mediates the 
isomerization of peptide bonds during protein synthesis57. Mutations of FKBP9 in mice causes behavioral 
abnormalities87 its protein product is expressed throughout the entire body58.  
 
rs2808290 (WEAF 50%, beta=0.0198, P-value=1.34x10-9) is located in an intergenic region, but overlaps 
with a regulatory feature (ENSR00001421990), a predicted enhancer, which is predicted to be active in 
osteoblast, myoblast and fibroblast cell lines75. The closest gene is protein coding MKX located 60kb 
downstream. The protein product of MKX is a transcription factor and regulates collagen expression and 
tendon development. Animal models of this gene show abnormal tendon and tail morphology88. 
 
rs116878242 (WEAF 7.5%, beta=0.033, P-value=3.14x10-8) resides in an intergenic region flanked by 
several non-coding genes. rs116878242 overlaps with an annotated promoter flanking region 
(ENSR00001537939) shown to be active in various cell types including fibroblasts89. The nearest protein-
coding gene is SOX9 over 100kb upstream, which is involved in sex determination, and is associated with 
height (intergenic rs1008388664, r2=0.061 with rs116878242, Table S14). SOX9 is also implicated in various 
monogenic diseases (Table S25) including campomyelic dysplasia, which includes a skeletal development 
phenotype90. 400bp away from rs116878242, there is a NF-κB transcription binding site, which has been 
shown to affect the expression of SOX991. 
 
Variants associated with BMI: 
 
rs62107261 (WEAF 4.7%, beta=-0.075, P-value=1.27x10-27) resides in the exon of a long intergenic non-
coding RNA (AC105393.2). The closest protein-coding gene is TMEM18, over 200kb upstream, which has 
previously been associated with BMI and obesity (Table S14). 
 
rs2003476 (WEAF 40.4%, beta= -0.025, P-value=5.89x10-13) resides in an intron of the transcription factor-
coding gene CRTC1. Crtc1-null mice are hyperphagic, obese, and infertile, and the Creb1- Crtc1 pathway 
mediates the central effects of hormones and nutrients on energy balance and fertility92. rs2003476 is 
associated with the expression of CRLF151, a protein coding gene 88kb upstream. CRLF1 expression 
changes significantly during human adipogenesis93. CRLF1 also shows differential expression levels in 
gluteal and abdominal subcutaneous adipose tissue in humans94. 
 
rs765876 (WEAF 48.8%, beta= -0.020, BMI P-value=9.64x10-10) resides in an intron  of HIVEP2, which 
codes for a transcription factor that binds to the enhancer sequences of various genes including 
somatostatin receptor II95. Mouse models of this gene show smaller body, with reduced fat mass96. 
 
Variants associated with hip circumference adjusted for BMI: 
 
rs10044000 (WEAF 39%, beta=0.0157, P-value=6.45x10-13) variant overlaps with the coding region of the 
gene CATSPER3 , where it causes a synonymous mutation. rs10044000 has been previously associated 
with height and  CATSPER3 is a known locus for height78,97 and bulimia98. rs10044000 has been shown to 
be an eQTL for PITX151 gene located 20kb upstream. The protein product of this gene is a transcription 
factor and involved in skeletal development99. Various congenital diseases are associated to this gene and 
all characterized by skeletal abnormalities100,101. Animal models also highlight the effect of this gene on 
skeletal development102. 
 
rs35874463 (WEAF 58.2%, beta=0.0374, P-value=9.26x10-17) results in an isoleucine to valine substitution 
in SMAD3. The substitution caused by this variant is predicted to be benign (Polyphen score = 0.007). 
Position 65 is directly adjacent to the metal binding site, which is required for the RNA binding function of 
the MH1 domain, valine is frequently found in the homolog position. Mutations of this gene were 
implicated in the aneurysms-osteoarthritis syndrome103, characterized by early onset osteoarthritis in the 
knees, hands and spine. Animal models of this gene shows a series of skeletal phenotypes104 highlighting 
the gene’s role in ossification and skeletal development. rs35874463 is also associated with height64 and  
heart developmental failures105.  
 
Variants associated with waist circumference adjusted for BMI: 
 
rs28610092 (WEAF 17%, beta= -0.021, P-value=8.92x10-16) resides in the promoter flanking region of 
PKD1, which has been found to be active in myoblasts, fibroblasts and osteoblasts75. rs28610092 is 
associated with the expression of PKD151. Although the primary function of this gene is the regulation of 
the development of the renal tubulogenesis106 and is the primary causal gene for adult type-1 polycystic 
kidney disease107, animal models show diverse phenotypes including defects in the myoskeletal 
development108.  
 
rs577721086 (WEAF 5.1%, beta=0.056, P-value=2.54x10-39) is located in the 5’ untranslated region of 
RSPO3, its position is highly conserved (GERP score=3.77) and has a number of epigenetic marks 
indicative of being an active promoter in several tissues55, GWAVA109 score=0.63. Intronic variation at this 
locus has previously been associated with waist circumference and waist to hip ratio adjusted for BMI 
(Table S14) and whilst collider bias might have complicated the interpretation of this signal110, it appears 
to be a genuine contributor to variance in waist circumference relative to trunk and not BMI (stage 1 P-
value=0.14) (Figure S27). rs577721086 has been previously associated with waist to hip ratio adjusted for 
BMI (Table S14). 
 
Variants associated with other anthropometric traits: 
 
rs11042397 is associated with hip circumference (WEAF 56.4%, beta= 0.047, P-value=5.20x10-11) and is 
located in an intron of ZNF143, which codes for a transcription factor involved in early developmental 
processes in animal models111. rs11042397 is tagged in HapMap by rs2290424 (r2=0.963) with P-
value=0.02112. rs11042397 is located 161kb upstream of SWAP70 , known for affecting bone mass and 
osteoclast function through modulating f-actin113 and 187kb away from TMEM49B, implicated in 
metabolic processes in animal  models114. 
 
rs62065847 is associated with waist circumference (WEAF 48.6%, beta= -0.022, P-value=2.86x10-11). This 
intergenic variant resides in a reported enhancer115 and is associated with the expression of many genes 
in close proximity including HOXB2, which is involved in skeletal abnormalities in animal models116,117. 
 
rs2082881 is a novel TRFM signal (WEAF 24.4%, beta=0.0834, P-value=9.91x10-9), but it is a known variant 
for BMI and height. rs2082881 overlaps with an intron of CENPO, which has been associated with 
height64. Animal models of this gene shows increased body length71. rs2082881 is an eQTL for other genes 
including NCOA1 and ADCY351. NCOA1 is a nuclear receptor coactivator, involved in the coactivation of 
steroid hormone receptors and activates the expression of a series of genes involved in development. 
Mouse model of this gene shows diverse phenotypes including obesity118. Several obesity and obesity 
related signals were associated to ADCY3, whose protein product, through its adenyl-cyclase activity, is an 
important regulator of energy balance.  
 
rs6901225 is a novel association for weight (WEAF 12%, beta=-0.0377, P-value=4.20x10-13) and is a known 
variant for height. Although the variant is located in the intergenic region, it is associated with the 
expression of multiple transcription factors51 such as ZNF322 and ABT1. ZNF322, a zinc-finger protein, is  
responsible for the regulation of many embryonic genes119. ABT1 interacts with IGHMBP2, which is 
important for skeletal phenotypes120.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S1: Study design for single marker tests. 
 
 
 
 
 
  
 
Figure S2: A minor allele frequency (MAF) histogram of variants that have passed the imputation 
quality threshold (0.4) across the imputed datasets that are available genome-wide. 
In the left graph we plotted the whole MAF range (0.01% -50%) and in the right graph we zoomed in MAF 
between 0.01% -5%. The y-axis is the average number of variants across our genome-wide imputed 
datasets (arcOGEN, UKHLS, ALSPAC, TwinsUK, 1958 Birth Cohort, INGI-Carl, INGI-FVG, HELIC MANOLIS, 
HELIC Pomak, INCIPE1, INCIPE2, LURIC, Rotterdam Study-1, Rotterdam Study-2, Rotterdam Study-3, 
TEENAGE, INGI-VB and UK Biobank). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S3: Summary plots of body mass index (BMI) sex-combined meta-analysis.  
Quantile-quantile plot of SNP associations. All SNPs are plotted in black, after excluding previously known 
loci (±500 kb) in blue, and after excluding previously known and common loci (±500 kb) in red. Manhattan 
plot showing in green loci with P≤10-8. Loci with P≤10-7 are labeled with the nearest protein coding gene 
in grey if they are known and in red if they are novel. The reported gene is the closest in physical distance. 
The horizontal line is drawn at 10-7. 
  
 
Figure S4: Summary plots of height sex-combined meta-analysis.  
Quantile-quantile plot of SNP associations. All SNPs are plotted in black, after excluding previously known 
loci (±500 kb) in blue, and after excluding previously known and common loci (±500 kb) in red. Manhattan 
plot showing in green loci with P≤10-8. Loci with P≤10-7 are labeled with the nearest protein coding gene 
in red if they are novel. The reported gene is the closest in physical distance. The horizontal line is drawn 
at 10-7. Only novel signals are annotated for Height, to avoid overcrowding in the graph. 
 
  
Figure S5: Summary plots of weight sex-combined meta-analysis.  
Quantile-quantile plot of SNP associations. All SNPs are plotted in black, after excluding previously known 
loci (±500 kb) in blue, and after excluding previously known and common loci (±500 kb) in red. Manhattan 
plot showing in green loci with P≤10-8. Loci with P≤10-7 are labeled with the nearest protein coding gene 
in grey if they are known and in red if they are novel. The reported gene is the closest in physical distance. 
The horizontal line is drawn at 10-7. 
 
  
 
Figure S6: Summary plots of total fat mass (TFM) sex-combined meta-analysis.  
Quantile-quantile plot of SNP associations. All SNPs are plotted in black, after excluding previously known 
loci (±500 kb) in blue, and after excluding previously known and common loci (±500 kb) in red. Manhattan 
plot showing in green loci with P≤10-8. Loci with P≤10-7 are labeled with the nearest protein coding gene 
in grey if they are known and in red if they are novel. The reported gene is the closest in physical distance. 
The horizontal line is drawn at 10-7. 
 
Figure S7: Summary plots of total lean mass (TLM) sex-combined meta-analysis.  
Quantile-quantile plot of SNP associations. All SNPs are plotted in black, after excluding previously known 
loci (±500 kb) in blue, and after excluding previously known and common loci (±500 kb) in red. Manhattan 
plot showing in green loci with P≤10-8. Loci with P≤10-7 are labeled with the nearest protein coding gene 
in grey if they are known and in red if they are novel. The reported gene is the closest in physical distance. 
The horizontal line is drawn at 10-7. 
 
 
 
 
 
Figure S8: Summary plots of trunk fat mass (TRFM) sex-combined meta-analysis.  
Quantile-quantile plot of SNP associations. All SNPs are plotted in black, after excluding previously known 
loci (±500 kb) in blue, and after excluding previously known and common loci (±500 kb) in red. Manhattan 
plot showing in green loci with P≤10-8. Loci with P≤10-7 are labeled with the nearest protein coding gene 
in grey if they are known and in red if they are novel. The reported gene is the closest in physical distance. 
The horizontal line is drawn at 10-7. 
 
 
  
Figure S9: Summary plots of waist circumference sex-combined meta-analysis.  
Quantile-quantile plot of SNP associations. All SNPs are plotted in black, after excluding previously known 
loci (±500 kb) in blue, and after excluding previously known and common loci (±500 kb) in red. Manhattan 
plot showing in green loci with P≤10-8. Loci with P≤10-7 are labeled with the nearest protein coding gene 
in grey if they are known and in red if they are novel. The reported gene is the closest in physical distance. 
The horizontal line is drawn at 10-7. 
 
 
 
 
 
Figure S10: Summary plots of hip circumference sex-combined meta-analysis.  
Quantile-quantile plot of SNP associations. All SNPs are plotted in black, after excluding previously known 
loci (±500 kb) in blue, and after excluding previously known and common loci (±500 kb) in red. Manhattan 
plot showing in green loci with P≤10-8. Loci with P≤10-7 are labeled with the nearest protein coding gene 
in grey if they are known and in red if they are novel. The reported gene is the closest in physical distance. 
The horizontal line is drawn at 10-7. 
 
 
 
Figure S11: Summary plots of waist-to-hip ratio (WHR) sex-combined meta-analysis.  
Quantile-quantile plot of SNP associations. All SNPs are plotted in black, after excluding previously known 
loci (±500 kb) in blue, and after excluding previously known and common loci (±500 kb) in red. Manhattan 
plot showing in green loci with P≤10-8. Loci with P≤10-7 are labeled with the nearest protein coding gene 
in grey if they are known and in red if they are novel. The reported gene is the closest in physical distance. 
The horizontal line is drawn at 10-7. 
 
 
 
  
Figure S12: Summary plots of waist circumference adjusted for BMI sex-combined meta-analysis.  
Quantile-quantile plot of SNP associations. All SNPs are plotted in black, after excluding previously known 
loci (±500 kb) in blue, and after excluding previously known and common loci (±500 kb) in red. Manhattan 
plot showing in green loci with P≤10-8. Loci with P≤10-7 are labeled with the nearest protein coding gene 
in grey if they are known and in red if they are novel. The reported gene is the closest in physical distance. 
The horizontal line is drawn at 10-7. 
 
 
  
Figure S13: Summary plots of hip circumference adjusted for BMI sex-combined meta-analysis.  
Quantile-quantile plot of SNP associations. All SNPs are plotted in black, after excluding previously known 
loci (±500 kb) in blue, and after excluding previously known and common loci (±500 kb) in red. Manhattan 
plot showing in green loci with P≤10-8. Loci with P≤10-7 are labeled with the nearest protein coding gene 
in grey if they are known and in red if they are novel. The reported gene is the closest in physical distance. 
The horizontal line is drawn at 10-7. 
 
 
  
 
Figure S14: Summary plots of wait-to-hip ratio (WHR) adjusted for BMI sex-combined meta-analysis.  
Quantile-quantile plot of SNP associations. All SNPs are plotted in black, after excluding previously known 
loci (±500 kb) in blue, and after excluding previously known and common loci (±500 kb) in red. Manhattan 
plot showing in green loci with P≤10-8. Loci with P≤10-7 are labeled with the nearest protein coding gene 
in grey if they are known and in red if they are novel. The reported gene is the closest in physical distance. 
The horizontal line is drawn at 10-7. 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Figure S15: Probability of regulatory function (PRF) plots for the newly identified loci.  
For each of the newly identified loci, we attempted to fine-map the association signal using epigenomic 
annotations (Methods). At each of the regions around the loci, the plots show the PRF scores for variants 
with high posterior probability of association, after combining association statistics with the PRF scores. 
Each variant is labeled with its association statistic rank, followed by the variant position (e.g. 1: 
chr2:407713). The height of the blue bar represents the PRF score itself, which is the sum of the 
contributions from individual annotations shown below. Annotations with negative enrichments 
(depletion of causal variants, e.g. H3K9me3) appear below zero in the PRF score breakdown. Regions with 
high confidence in fine-mapping are shown below (posterior probability of causality for the best SNP > 
0.5).  
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Figure S16: Genomic Evolutionary Rate Profiling (GERP) score as a measure of cross-species 
conservation of the sequences around each newly identified association.  
A – variants listed in Table 1; B – variants listed in Table 2. The GERP score is based on the analysis of the 
alignment of sequences from 29 mammalian species and captures substitution deficits indicating 
sequence conservation. A score above zero indicates substitution deficit and thus indicates that a site 
may be under evolutionary constraint. Negative scores indicate substitution surplus. Stretches of scores 
close to zero indicate regions where the alignment is too shallow to get a meaningful estimate of the 
constraint. In practice, a position with GERP score above two is considered to be conserved (this 
threshold is indicated by the light blue background on the plots). To put the conservation pattern in a 
genic context, the transcripts of genes located within 500bp of the signals are also shown (annotation 
from GENCODE release 19). To make the trends in conservation more visible in the plots, GERP scores 
were averaged in two base pairs long sliding window. The red line indicates the position of the variant.  
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BMI: body mass index; WHR: waist to hip ratio;  
 
Figure S17: Enrichment in discovery meta-analysis using independent variants (r2<0.2) with MAF ≥ 0.1% 
(a) and after excluding previously known loci (±500kb) (b).  
Enrichment of signal is observed if the P-value (one-sided, denoted by the red dot) from the binomial test 
of observed versus expected number of variants with P≤10-5 is less than 0.05/4.482 (5% significance level 
Bonferroni corrected for the effective number of independent traits; horizontal red line). The enrichment 
in height using all variants in (a) is too significant to be calculated with precision (~3M independent 
variants with MAF≥0.1%, 642 of which have P≤10-5, 31 expected). Observed and expected counts, 
Bonferroni corrected P-values and FDR q-values are given in Table S11.  
WaistBMIadj: waist circumference adjusted for BMI; HipBMIadj: hip circumference adjusted for BMI; 
WHRBMIadj: waist to hip ratio adjusted for BMI; TFM: total fat mass; TLM: total lean mass; TRFM: trunk 
fat mass. 
 All Novel 
0.1%≤MAF≤1% 
  
1%<MAF≤5% 
  
MAF>5% 
  
BMI: body mass index; WHR: waist to hip ratio; WaistBMIadj: waist circumference adjusted for BMI; 
HipBMIadj: hip circumference adjusted for BMI; WHRBMIadj: waist to hip ratio adjusted for BMI; TFM: 
total fat mass; TLM: total lean mass; TRFM: trunk fat mass 
Figure S18: Enrichment in discovery meta-analysis results. Using independent variants (r2<0.2) 
within different Minor Allele Frequency (MAF) bins (left) and after excluding previously known loci 
(±500 kb) (right). Enrichment of signal is observed if the P-value from the binomial test of observed 
versus expected number of variants with P≤10-5 is less than 0.05/4.482 (5% significance level 
Bonferroni corrected for the effective number of independent traits (horizontal red line). 
All Novel 
0.1%≤MAF≤1% 
  
1%<MAF≤5% 
  
MAF>5% 
  
BMI: body mass index; WHR: waist to hip ratio; WaistBMIadj: waist circumference circumference 
adjusted for BMI; HipBMIadj: hip circumference adjusted for BMI; WHRBMIadj: waist to hip ratio adjusted 
for BMI; TFM: total fat mass; TLM: total lean mass; TRFM: trunk fat mass 
 
Figure S19: Enrichment of discovery meta-analysis results in Mendelian genes for height.  
We used independent variants (r2<0.2) within different Minor Allele Frequency (MAF) bins (left) and after 
excluding previously known loci (±500 kb) (right). Enrichment of signal is observed if the P-value from the 
binomial test of observed versus expected number of variants with P≤10-5 in Mendelian genes for height 
(as calculated by GREAT) is less than 0.05/4.482 (5% significance level Bonferroni corrected for the 
effective number of independent traits (horizontal red line). 
 
All Novel 
0.1%≤MAF≤1% 
  
1%<MAF≤5% 
  
MAF>5% 
 
 
BMI: body mass index; WHR: waist to hip ratio; WaistBMIadj: waist circumference adjusted for BMI; 
HipBMIadj: hip circumference adjusted for BMI; WHRBMIadj: waist to hip ratio adjusted for BMI; 
TFM: total fat mass; TLM: total lean mass; TRFM: trunk fat mass 
 
Figure S20: Enrichment of discovery meta-analysis results in monogenic obesity genes.  
We used independent variants (r2<0.2) within different Minor Allele Frequency (MAF) bins (left) and after 
excluding previously known loci (±500 kb) (right). Enrichment of signal is observed if the P-value from the 
binomial test of observed versus expected number of variants with P≤10-5 in Mendelian genes for obesity 
(as calculated by GREAT) is less than 0.05/4.482 (5% significance level Bonferroni corrected for the 
effective number of independent traits (horizontal red line). 
 
 
  
  
  
 
  
Figure S21: Beta-beta plots. 
Effect sizes in our discovery phase (x-axis) versus effect sizes of previously published associations (y-axis) 
for variants associated with: A. BMI from Locke et al, R-squared: 0.563; B. TFM from Lu et al, R-squared: 
0.267; C. waist circumference from Shungin et al, R-squared: 0.701; D. waist circumference adjusted for 
BMI from Shungin et al, R-squared: 0.489; E. hip circumference from Shungin et al, R-squared: 0.623; F. 
hip circumference adjusted for BMI from Shungin et al, R-squared: 0.427; G. WHR from Shungin et al, R-
squared: 0.397; H. WHR adjusted for BMI from Shungin et al, R-squared: 0.215. The blue line is drawn at 
y=x. The red line is the observed correlation coefficient of x and y. 
  
 
 Figure S22: Locus zoom and forest plots for the novel loci reported in Table 1.  
Plots display 500kb each side of the top variant, where the smaller diamond represents the discovery P-
value and the bigger diamond the overall P-value (meta-analysis across discovery and follow-up cohorts). 
LD is calculated from the combined WGS UK10K cohorts (ALSPAC and TwinsUK). Previously reported 
variants are denoted by large circles.  
 
  
 
 
 
 
 
 
 Figure S23: Locus zoom and forest plots for the novel loci reported in Table 2.  
Plots display 500kb each side of the top variant, where the smaller diamond represents the discovery P-
value and the bigger diamond the overall P-value (meta-analysis across discovery and follow-up cohorts). 
LD is calculated from the combined WGS UK10K cohorts (ALSPAC and TwinsUK). Previously reported 
variants are denoted by large circles. 
 
 
  
Figure S24: Study design for rare variants tests. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure S25: Meta-analysis P-values (top) and effect sizes (bottom) of variants associated with height 
across discovery cohorts and UKBiobank using METACARPA and METAL. 
 
A        B 
 
C        D 
 
E        F 
 
 
Figure S26: Venn diagrams showing overlap of the 106 signals from Tables 1, 2 and S3 robustly 
associated with an anthropometric trait at P-value ≤ 5x10-8 in stage1+stage2 with other anthropometric 
traits also associated at P-value ≤ 5x10-8 in stage1+stage2. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S27: No evidence of collider bias for traits adjusted for BMI or Height.  
Effect sizes of independent (pairwise r2<0.2 and further than 500kb) SNPs suggestive (P<10-5) for waist 
circumference, hip circumference and waist to hip ratio adjusted for BMI (R-squared 0.11, 0.0051, 0.004 
respectively) versus effect sizes for BMI. Similarly, effect sizes of independent SNPs suggestive for total fat 
mass, total lean mass and trunk fat mass (R-squared 0.0003, 0.0007, 0.0011 respectively) versus effect 
sizes for height. 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Figure S28: Combined information from two fine-mapping methods, functional prediction scores and 
eQTL analysis to assess the overall evidence supporting functional and causal interpretation at 30 fine-
mapped regions (Table S5) of the 106 newly indentifind variants.  
The panels (from top to bottom) show the LocusZoom regional association plot; posterior probability (PP) 
statistics from the fine-mapping methods CAVIARBF and PRFScore (only variants with PP>0.1 in either 
methods are shown); Genome Wide Annotation of Variants (GWAVA) scores ; Genomic Evolutionary Rate 
Profiling (GERP) scores; average GERP (in a 100bp window around each variant) scores; if the variant is an 
eQTL signal; number of cell lines in which the variant overlaps with a DNase footprints (peak calls from 
ENCODE); number of overlapping transcriptional factor binding sites based on ENCODE and JASPAR ChIP-
seq; number of cell lines in which the queried locus overlaps with a DNase hypersensitivity site (ENCODE 
data, peaks from Ensembl); and Variant Effect Predictor (VEP) genic annotation. Circle sizes and colors for 
all scores are scaled with respect to score type and numbers are plotted below each circle. GWAVA scores 
range between [0,1]  and scores over 0.5 indicate functionality (coloured in shades of green for scores 
<0.5 and red for scores >0.5). GERP scores range between [-12.3,6.17]  and scores above zero indicate 
constrain (coloured in shades of green for scores <0 and red for scores >0).  
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Figure S29: Garfield plots for mQTL enrichment. 
Radial plots show the fold enrichment for each time-point where methylation profiles were measured at 
different GWAS significance thresholds. Small dots on the outer side of the plots show if the observed 
enrichment is significant for thresholds 10-5, 10-6, 10-7, 10-8 in direction from outside to inside. 
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Figure S30: Power benefits due to imputation with UK10K+1000GP compared to 1000GP alone.  
Strength of single-variant associations detectable at 80% power as a function of Minor Allele Frequency 
(MAF) and sample size. Using data from chromosome 20, we calculated the smallest value of the strength 
of association beta (measured in standard deviations), that would be detectable under a linear dosage 
model at the genome-wide significance threshold (P<1.85x10-9), given the MAF and r2 of each variant 
imputable from both the 1000GP and the UK10K+1000GP reference panels, for three representative 
sample sizes of our discovery stage (N=15,201 representing TFM, TLM, TRFM; N=37,159 representing 
WHR and hip circumference adjusted/unadjusted for BMI; and N=57,129 representing height, BMI, 
weight, waist circumference adjusted/unadjusted for BMI). The averages of these minimum detectable 
beta values by MAF and sample size are shown. 
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Figure S31: Imputation accuracy scores (top) and P-values (bottom) of variants imputed in UKHLS using 
UK10K+1000GP compared to 1000GP alone. 
 
 
Effect size MAF 
Sample size 0.001 0.01 0.05 0.1 0.15 0.2 0.25 0.3 0.35 0.4 0.45 0.5 
10K 1.407 0.447 0.204 0.149 0.125 0.111 0.103 0.097 0.093 0.091 0.089 0.089 
50K 0.63 0.2 0.091 0.066 0.056 0.05 0.046 0.043 0.042 0.041 0.04 0.04 
100K 0.446 0.142 0.064 0.047 0.039 0.035 0.032 0.031 0.03 0.029 0.028 0.028 
250K 0.282 0.09 0.041 0.03 0.025 0.022 0.021 0.019 0.019 0.018 0.018 0.018 
500K 0.199 0.063 0.029 0.021 0.018 0.016 0.015 0.014 0.013 0.013 0.013 0.012 
750K 0.163 0.052 0.024 0.017 0.014 0.013 0.012 0.011 0.011 0.01 0.01 0.01 
1M 0.141 0.045 0.02 0.015 0.012 0.011 0.01 0.009 0.009 0.009 0.009 0.009 
 
Figure S32: Effect sizes detectable with 80% power at the genome-wide significance threshold, P<5x10-
8,  as a function of minor allele frequencies and sample size. 
 
 
 
 
 
 
 
 
 
Trait BMI Weight Height TFM TLM TRFM Waist Hip WHR WaistBMIadj HipBMIadj WHRBMIadj 
ALSPAC WGS 1791 1812 1794 1683 1683 1683 1807 1808 1806 1785 1786 1784 
TwinsUK WGS 1747 1747 1747 1716 1716 1716 1265 1266 1265 1265 1266 1265 
ALSPAC GWA 4101 4132 4103 3815 3815 3815 4121 4115 4116 4121 4115 4116 
TwinsUK GWA 3539 3539 3540 3275 3275 3275 2585 2582 2582 2583 2580 2580 
1958 Birth Cohort 8015 8053 8080 -- -- -- 8106 8091 8105 8027 8014 8025 
INGI Friuli Venezia Giulia  1170 1172 1197 -- -- -- 791 701 791 790 831 790 
INCIPE 1 934 933 937 -- -- -- 934 -- -- 932 -- -- 
INCIPE 2 2035 2056 2056 -- -- -- 2050 -- -- 2043 -- -- 
LURIC 1569 1570 1570 -- -- -- 1546 1547 1543 1546 1547 1543 
Rotterdam 1 5954 5970 5961 2387 2386 2513 5665 5660 5660 5565 5561 5561 
Rotterdam 2 2148 2148 2151 747 747 747 1938 1937 1937 1935 1934 1934 
Rotterdam 3 3017 3017 3018 1578 1578 2488 2930 2931 2928 2919 2921 2917 
TEENAGE 701 703 703 -- -- -- 698 701 697 698 701 697 
INGI‐Val Borbera  1778 1779 1785 -- -- -- 1754 -- -- 1754 -- -- 
INGI Carlantino 472 472 471 -- -- -- 397 400 388 397 400 388 
HELIC MANOLIS 1019 1051 1043 -- -- -- 1060 1050 1053 1005 998 1001 
HELIC Pomak 932 942 933 -- -- -- 887 883 879 875 871 867 
arcOGEN 3908 3923 3925 -- -- -- -- -- -- -- -- -- 
UKHLS 8560 8620 8700 -- -- -- 8727 -- -- 8513 -- -- 
FINRISK 1249 1249 1249 -- -- -- 1254 1254 1254 1247 1247 1247 
LOLIPOP_EW610 915 916 927 -- -- -- 914 916 919 909 909 909 
LOLIPOP_EW_A 589 589 589 -- -- -- 587 587 587 587 587 587 
LOLIPOP_EW_P 650 650 650 -- -- -- 649 649 649 649 649 649 
Total discovery (stage 1) 56793 57043 57129 15201 15200 16237 50665 37078 37159 50145 36917 36860 
Fenland 9101 9103 9106 8662 8661 8662 9100 9079 9082 9094 9077 9076 
Copenhagen 28710 28736 28745 -- -- -- 28687 28668 28677 28643 28631 28632 
GenerationR -- -- -- 2008 2015 2005 -- -- -- -- -- -- 
SardiNIA 6481 6480 6480 -- -- -- 6483 6481 6481 6483 6481 6481 
GoT2D 32022 -- 27544 -- -- -- 29328 28680 28686 29320 28678 28684 
UK Biobank 134509 134570 134798 -- -- -- 134798 134650 134795 134584 134455 134594 
Total follow-up (stage 2) 210823 178889 206673 10670 10676 10667 208396 207558 207721 208124 207322 207467 
Total discovery + follow-up   
(stage 1 + stage 2) 267616 235932 263802 25871 25876 26904 259061 244636 244880 258269 244239 244327 
BMI: body mass index; WHR: waist to hip ratio; WaistBMIadj: waist circumference adjusted for BMI; 
HipBMIadj: hip circumference adjusted for BMI; WHRBMIadj: waist to hip ratio adjusted for BMI; TFM: 
total fat mass; TLM: total lean mass; TRFM: trunk fat mass 
Table S1: Sample sizes for the 12 anthropometric traits studied 
 
 
 
 
 
 
 
 
 
 
 
Trait 
Independent 
known 
variants 
Same 
direction of 
effect 
Binomial test P 
Source of known 
variants 
BMI 97 96 <2.2x10-16 Locke et al 2015 
Weight 14 14 6.1x10-5 Thorleifsson et al 2009 
Height 619 610 <2.2x10-16 Wood et al 2015 
TFM 12 12 2.44x10-4 Lu et al 2016 
Waist 45 44 1.31x10-12 Shungin et al 2015 
Hip 63 61 <2.2x10-16 Shungin et al 2015 
WHR 28 27 1.08x10-7 Shungin et al 2015 
WaistBMIadj  70 70 <2.2x10-16 Shungin et al 2015 
HipBMIadj  89 89 <2.2x10-16 Shungin et al 2015 
WHRBMIadj  39 39 1.82x10-12 Shungin et al 2015 
BMI: body mass index; WHR: waist to hip ratio; WaistBMIadj: waist circumference adjusted for 
BMI; HipBMIadj: hip circumference adjusted for BMI; WHRBMIadj: waist to hip ratio adjusted for 
BMI; TFM: total fat mass; TLM: total lean mass; TRFM: trunk fat mass 
 
Table S13: Comparison of direction of effect between betas from our discovery phase and known loci.  
There are 28 variants reported for weight in Table 2 of Thorleifsson et al 2009, 14 of which are 
independent of each other (r2<0.2 and 500 kb away from each other). From the 697 variants associated 
with height by Wood et al 2015, we kept the ones that were GWAS significant from the single-point 
analysis (623 remained) and we further excluded 4 non-distinct signals (r2>0.2 within 500 kb). For body 
shape phenotypes, we also took forward independent variants identified in European and sex-combined 
samples from Shungin et al 2015. 
 
 
 
Cohorts N of duplicate pairs 
(pi-hat>0.98) 
N of related pairs 
(pi-hat>0.2) 
N of total pairs 
(N1 x N2) 
1958 Birth Cohort vs UKBB 40 178 5,847x138,990 
arcOGEN vs UKBB 63 194 2,762x138,990 
GWAS TwinUK vs UKBB 68 243 3,980x138,990 
UKHLS vs UKBB 88 450 9,175x138,990 
WGS TwinsUK vs UKBB 43 117 1,754x138,990 
Total 302 1,182 3,268,766,820 
Table S19: Number of overlapping (pi-hat > 0.98) and related (pi-hat > 0.2) pairs between UK-based 
cohorts and UK Biobank (UKBB).  
 
 
 
 
 
 
 
 
 
 
 Independent number of 
suggestive associations 
Opposite Direction of 
Effects with BMI or 
Height 
Proportion 
(%) 
Binomial P-
value 
WaistBMIadj 146 77 52.74 0.280 
HipBMIadj 155 57 36.77 1.000 
WHRBMIadj 86 49 56.98 0.118 
TFM 79 29 36.71 0.994 
TLM 79 40 50.63 0.500 
TRFM 82 33 40.24 0.970 
WaistBMIadj: waist circumference adjusted for BMI; HipBMIadj: hip circumference 
adjusted for BMI; WHRBMIadj: waist to hip ratio adjusted for BMI; TFM: total fat mass; 
TLM: total lean mass; TRFM: trunk fat mass 
 
Table S21: No evidence of collider bias for waist circumference adjusted for BMI analysis.  
Number of independent (pairwise r2<0.2 and further than 500kb) variants associated with WaistBMIadj, 
HipBMIadj, WHRBMIadj, TFM, TLM, TRFM in the discovery meta-analysis with P-value<10-5; number and 
proportion of those variants that had opposite direction of effects for WaistBMIadj, HipBMIadj, 
WHRBMIadj versus effect sizes for BMI and TFM, TLM, TRFM versus Height; binomial P-value of 
significance. 
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